Dr. Bertrand Routy MD, PhD is a clinician-scientist and associate professor in the department of hemato-oncology at the CHUM (University of Montreal). Upon his recruitment to the CRCHUM in 2018 after completing his PhD with Pr. Laurence Zitvogel, Dr. Routy quickly established himself as the scientific director of the CHUM Microbiome Centre where he began his work to develop novel microbiome-based therapeutics in oncology.

His work contributed to the discovery of the gut microbiome as a novel prognostic biomarker for immune checkpoint inhibitors (ICI) in various cancers. He characterized the deleterious impact of antibiotic-related gut dysbiosis on ICI outcomes, which led to pivotal changes in clinical oncology practice. Moreover, he demonstrated that modulation of the microbiome by fecal microbiota transplantation, probiotics, and prebiotic supplementation had the potential to circumvent ICI resistance. His team currently leads several microbiota-centered trials in oncology ranging from phase I to phase II trials, with the aim of decreasing primary ICI resistance.

Dr. Routy is internationally recognized as a leader in the microbiome field with more than 15,600 citations including publications in Science, Nature Medicine and Annals of oncology, and h-index of 42. Moreover, his unending commitment to improving immunotherapy responses in cancer patients has led to several awards from prestigious societies, including the FRQS 2023 Junior 2 ranked #1, the Prix de la Relève Scientifique du Québec in 2022 and the 2021 Gairdner Foundation award.